Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor.
Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death in Western countries. Most patients with prostate cancer respond to initial androgen deprivation therapy but eventually progress to castration-resistant prostate cancer (CRPC). Although androgen receptor signaling remains the main driver in CRPC, a growing body of evidence suggests that other pathways are involved in this progression. This article reviews the preclinical data and current status of clinical trials therapeutically targeting tubulin, DNA repair, molecular chaperones such as CLU and Hsp27, tyrosine kinases, and DNA repair.
Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
Yohann
Y
Loriot
Amina
A
Zoubeidi
Martin E
ME
Gleave
D001859:Bone Neoplasms / Q000188:drug therapy*; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004260:DNA Repair / Q000502:physiology; D000069439:Dasatinib; D018450:Disease Progression; D034261:Epothilones / Q000494:pharmacology / Q000627:therapeutic use; D050939:Gene Fusion; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary*; D019859:Proto-Oncogene Proteins c-met / Q000502:physiology; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D011944:Receptors, Androgen / Q000502:physiology; D043823:Taxoids / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use
D034261:Epothilones; D011743:Pyrimidines; D011944:Receptors, Androgen; D043823:Taxoids; D013844:Thiazoles; C552428:cabazitaxel; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; C430592:ixabepilone; D000069439:Dasatinib